The dark side of glucose

Nature Medicine

Volumn 1, Issue 10, 1995, Pages 1002-1004

  Schmidt, Ann Marie ^a   Du Yan, Shi ^a   Stern, David M ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

DIABETES MELLITUS; GLYCATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

DIABETES MELLITUS; GLUCOSE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN;

EID: 0028834378     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1095-1002     Document Type: Article

References (18)

1. Li, Y-M., Tan, A.X. & Vlassara, H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of AGE-modifíed proteins to a conserved motif. Nature Med. 1, 1057-1061 (1995).
2. Ruderman, N., Wiliamson, J. & Brownlee M. Glucose and diabetic vascular disease. FASEB J. 6, 2905-2914 (1992).
3. Harrington, C. & Colaco, C.A.L.S. Alzheimer’s disease: A glycation connection. Nature 370, 247-248 (1994).
4. 2-Microglobulin modified with AGEs is a major component of hemodialysis-associated amyloidosis. J. clin. Invest. 92, 1243-1252 (1993).
5. Yan, S-D. et al. Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nature Med. 1, 693-699 (1995).
6. Vitek, M. et al. AGEs contribute to amyloidosis in Alzheimer’s disease. Proc. natn. Acad. Sci. U.S.A. 91, 4766-4770 (1994).
7. Smith, M. et al. Advanced maillard reaction end-products are associated with Alzheimer disease pathology. Proc. natn. Acad. Sci. U.S.A. 91, 5710-5714 (1994).
8. Palinski, W. et al. Immunological presence of AGEs in atherosclerotic lesions of euglycemic rabbits. Arterioscl. Thromb. Vase. Biol. 15, 571-582 (1995).
9. Kirstein, M. et al. AGE induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging. Proc. natn. Acad. Sci. U.S.A. 87, 9010-9014 (1990).
10. Schmidt, A-M. et al. Regulation of human mononuclear phagocyte migration by cell surface binding proteins for AGEs. J. clin. Invest. 91, 2155-2168 (1993).
11. Vlassara H., Bucala, R. & Striker L. Pathogenic effects of AGEs: Biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70, 138-151 (1994).
12. Schmidt, A-M. et al. Cellular receptors for AGEs: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arteroscler. Thromb. 14, 1521-1528 (1994)
13. Khoury, J. et al. Macrophages adhere to glucose-modified basement membrane via their scavenger receptors. J. biol. Chem. 269, 10197-10200 (1994).
14. Schmidt, A-M., Hori, O., Chen, J., Brett, J. & Stern, D. AGE interaction with their endothelial receptor induces expression of VCAM-1: A potential mechanism for the accelerated vasculopa-thy of diabetes. J. clin Invest. 96, 1375-1403 (1995).
15. Li, H., Cybulsky, M., Gimbrone, M. & Libby, P. An atherogenic diet rapidly induces VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arteroscler. Thromb. 13, 197-204 (1993).
16. Hori, O. et al. RAGE is a cellular binding site for amphoterin: Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J. biol Chem. (in the press).
17. Schmidt, A-M. et al. The endothelial binding site for AGEs consists of a complex: An integral membrane protein and a lactoferrin-like polypeptide. J. biol. Chem. 269, 9882-9888 (1994).
18. Marhoffer, W., Stein, M., Maeser, E. & Federlin, K. Impairment of polymorphonuclear leukocyte function and metabolic control for diabetes. Diabetes Care 15, 256-260 (1992).